Verquvo

 Research in the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic GMP (cGMP) pathway showed that impaired NO–sGC signaling is central in heart failure, reducing vascular tone and worsening cardiac function.

 Vericiguat is the first sGC stimulator approved for heart failure with reduced ejection fraction.

                                      

                                                                Victoria Trial  VERQS 

VICTORIA Trial (2016–2019)

• Large Phase III trial with 5,050 patients who had worsening HFrEF.
• Vericiguat significantly reduced the composite endpoint of cardiovascular death or heart failure hospitalization.
• Results published in NEJM (2020), establishing its clinical benefit.

January 2021: FDA approved Vericiguat (brand name Verquvo, developed by Bayer/Merck) for chronic HFrEF patients with recent decompensation.

July 2021: EMA approved Vericiguat in the European Union.

Snapshot